Form 4: Moderna Director Noubar Afeyan Acquires Stock Options

Director Noubar Afeyan acquired stock options in Moderna, Inc. on May 6, 2024.

Summary

• On May 6, 2024, Noubar Afeyan, a director of Moderna, Inc., acquired stock options.
• The stock options grant the right to buy 7,557 shares of Moderna's common stock at an exercise price of $122.13.
• These options will fully vest and become exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, contingent upon continued service.
• Following the transaction, Afeyan directly owns 7,557 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a director's stock option grant. While insider buying can be seen as positive, this is an option grant, which is part of compensation.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding Moderna's future performance, but the vesting of the options is contingent on continued service, suggesting an expectation of ongoing involvement.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Option grants are a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry, used to align management's interests with those of shareholders.
• The size of the grant (7,557 shares) would need to be compared against grants to directors at comparable companies like BioNTech, Pfizer, or Novavax to assess its relative significance.

Stakeholder Impact

• The granting of stock options to a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates